Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tokyo-based pharmaceutical company, Kyowa Hakko Kirin has commenced the launch of Nauzelin Orally Disintegrating (OD) Tablets formulation, used to treat diseases of the gastrointestinal tract.
Subscribe to our email newsletter
The Nauzelin OD Tablets formulation includes Nauzelin OD Tablets 5 and Nauzelin OD Tablets 10.
The new Nauzelin orally disintegrating tablet formulation has been developed by Kyowa Hakko Kirin, using the Solblet technology, for which Kyowa Hakko Kirin holds the patent.
The tablets designed to dissolve easily can be used by patients who have difficulty in swallowing, such as infants and elderly people, and by people in workplaces or other situations where it is difficult to access or drink water.
With the launch of OD tablet formulation, Nauzelin is now available as tablets, granules, dry syrup, suppositories, and OD tablets.